An Activist’s Protocol Review Toolkit
An Activist’s Protocol Review Toolkit is designed to facilitate community participation in the development and review of clinical trials protocols.
An Activist’s Protocol Review Toolkit is designed to facilitate community participation in the development and review of clinical trials protocols.
As we close another year of unprecedented challenges and achievements, I'm honored to share with you Treatment Action Group's (TAG) 2022 Annual Report.
On 15 June, 2023, TB Europe Coalition (TBEC) organized a webinar featuring a presentation by Treatment Action Group’s TB Project Officer, David Branigan, on the practical actions advocates can take to promote the adoption and scale up of shorter, safer 1/4/6 regimens for TB prevention and the treatment of drug-sensitive and drug-resistant TB as well as supportive diagnostics.
Supporting, Mobilizing, and Accelerating Research for Tuberculosis Elimination (SMART4TB) is a five-year cooperative agreement made possible by the United States Agency for International Development (USAID), with the assistance of the American people, that aims to transform tuberculosis (TB) prevention and care.
This policy brief explores barriers such as the high-burden among marginalized communities, the complicated diagnostic process, and the difficulties of finding the missing millions of people with HCV in most high-burden countries.
Save the date for Monday, October 19! TAG’s 2023 Research in Action Awards will honor some of the best and brightest activists, scientists, and leaders in the fight to end HIV, tuberculosis, and hepatitis C across the U.S. and around the world.
TAG prepared these remarks to deliver at multistakeholder hearings on health held on May 8 and 9, 2023, at the United Nations Headquarters in New York City.
In 2020, health authorities and drug manufacturers identified a type of chemical impurity called nitrosamines in rifampicin and rifapentine, two essential medicines used in the treatment and prevention of TB. TAG and IMPAACT4TB project partners have developed several materials to…
The Indian Patent Office has taken a laudable step that will pave the way for generic manufacturing of a key tuberculosis (TB) drug.
All people affected by TB have a right to benefit from scientific progress and to access the best-available short-course regimens for TB prevention and treatment. The 1/4/6x24 Campaign demands that countries and other duty bearers take action to implement the…